BzATP triethylammonium salt
目录号 : KM4671 纯度 : ≥95%

BzATP triethylammonium salt 是一种 P2X 受体激动剂,对 P2X1,P2X2,P2X3,P2X2/3,P2X4 和 P2X7 的 pEC50 分别为 8.74,5.26,7.10,7.50, 6.19,6.31 和 5.33。BzATP triethylammonium salt 对 P2X7 受体有效,对大鼠 P2X7 和小鼠 P2X7 的EC50 分别为 3.6 μM 和 285 μM。

规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
25mg
In-stock
50mg 询价 In-stock
100mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

BzATP triethylammonium salt acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively. BzATP triethylammonium salt is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively.

IC50&Target

pEC50: 8.74 (P2X1), 5.26 (P2X2), 7.10 (P2X3), 6.19 (P2X2/3), 6.31 (P2X4), 5.33 (P2X7)
EC50 3.6 μM (rat P2X7); 285 μM (mouse P2X7)

体外研究

BzATP (10-1000 μM; 24 h) promotes the proliferation and migration of U87 and U251 glioma cells.
P2X7R protein expression is induced by BzATP (100 μM; 6-48 h) in human glioma cells.

Cell Proliferation Assay

Cell Line: U87 and U251 glioma cells
Concentration: 5, 10, 50, 100, 500 and 1000 μM
Incubation Time: 2, 6, 12, 24, 48 and 72 hours
Result: The proliferation of U87 and U251 glioma cell lines was significantly increased in the presence of 10-1000 uM and 100-1000 μM, respectively.
The peak of cell proliferation of both U87 and U251 cell lines was at 100 μM.
The optimal incubation time is 24 hours in both U87 and U251 cells lines.

Western Blot Analysis

Cell Line: U87 and U251 glioma cells
Concentration: 100 μM
Incubation Time: 6-48 hours
Result: Induced the upregulation of P2X7R.
体内研究

BzATP (5 mg/kg) significantly promotes P2X7R expression in the intestines compared with intestines in the sham group and the control group after cecal ligation and puncture (CLP) induction.

Animal Model: Male 2-month-old C57BL/6 mice (each weighing between 20 and 25 g)
Dosage: 5 mg/kg
Administration: Injected through the intraperitoneal route
Result: At 48 hours, mice in the treated group and control group exhibited mortalities of 91% and 86%, respectively.
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 250 mg/mL (245.35 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9814 mL 4.9069 mL 9.8138 mL
5 mM 0.1963 mL 0.9814 mL 1.9628 mL
10 mM 0.0981 mL 0.4907 mL 0.9814 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。